Surgical devices and technology provider
) recently announced plans to co-develop a sequence of educational
programs along with
). Exactech provides restoration products for bone and joint
replacement. The co-developed academic program is designed to
improve standards of care for patients across the spectrum of knee
and shoulder repair.
Conmed and Exactech plan to utilize their positional advantage
and expertise to enhance patient care. The exhaustive medical
educational program covers arthroscopic intervention to complete
joint replacement techniques and technologies. Development of
quarterly itinerary for the academic program to be launched in
early 2013 is underway.
Management at Conmed believes that the educational program will
provide a top-notch experience to surgeons and practitioners in
related fields. The company's alliance with Exactech will help to
develop a discursive approach to surgeon education and is expected
to improve the technical skill-set of the surgeons. The goal of the
program is to provide excellent educational experience to
The companies understand the need for advanced techniques to
treat the continuum of orthopaedic injuries and appropriate
training of surgeons. Furthermore, there is a lack of medical
programs to address injuries ranging from soft tissue damage to
joint disease. Consequently, management at Exactech asserts that
there should be a paradigm shift in orthopaedic educational
The educational programs will be carried out at Conmed
Linvatec's exclusive Center for Orthopaedic Education based in
Largo, Florida. Conmed Linvatec is a subsidiary of Conmed
Corporation. The joint development of the academic program will
also provide Conmed with an opportunity to exhibit its world-class
training facility in Largo to leading surgeons.
Conmed serves the arthroscopy, endosurgery and electrosurgery
market and produces cardiac disposables. It also offers various
training programs for clinicians. This underlines its commitment
towards enhanced patient care and improved clinical results. The
company serves a highly competitive market along with larger and
technically more proficient companies like
Smith & Nephew plc.
Conmed currently retains a Zacks #2 Rank, which translates into
a short-term 'Buy' rating. We maintain our long-term 'Neutral'
recommendation on the stock.
CONMED CORP (CNMD): Free Stock Analysis Report
COVIDIEN PLC (COV): Free Stock Analysis Report
EXACTECH INC (EXAC): Free Stock Analysis Report
SMITH & NEPHEW (SNN): Free Stock Analysis
STRYKER CORP (SYK): Free Stock Analysis Report
To read this article on Zacks.com click here.